Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.

4.4 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

Jaguar Health has received 87.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote “Outperform” if you believe JAGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Miscellaneous

Receive JAGX News and Ratings via Email

Sign-up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.

Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions

How has Jaguar Health's stock been impacted by COVID-19 (Coronavirus)?

Jaguar Health's stock was trading at $0.45 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JAGX shares have increased by 4.0% and is now trading at $0.4680. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jaguar Health.

When is Jaguar Health's next earnings date?

How were Jaguar Health's earnings last quarter?

Jaguar Health Inc (NASDAQ:JAGX) announced its quarterly earnings data on Friday, May, 15th. The biotechnology company reported ($0.56) earnings per share for the quarter. The biotechnology company had revenue of $0.87 million for the quarter. Jaguar Health had a negative return on equity of 538.90% and a negative net margin of 755.26%. View Jaguar Health's earnings history.

What price target have analysts set for JAGX?

2 equities research analysts have issued twelve-month price objectives for Jaguar Health's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Jaguar Health's share price to reach $4.00 in the next year. This suggests a possible upside of 754.7% from the stock's current price. View analysts' price targets for Jaguar Health.

Has Jaguar Health been receiving favorable news coverage?

News coverage about JAGX stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Jaguar Health earned a news impact score of 1.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutJaguar Health.

When did Jaguar Health IPO?

(JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.16%). Company insiders that own Jaguar Health stock include James J Bochnowski, Jonathan B Siegel, Lisa A Conte and Nantucket Investments Ltd. View institutional ownership trends for Jaguar Health.

Which institutional investors are buying Jaguar Health stock?

JAGX stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Jaguar Health stock in the last two years include James J Bochnowski, Jonathan B Siegel, and Lisa A Conte. View insider buying and selling activity for Jaguar Health.

How do I buy shares of Jaguar Health?

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $0.47.

How big of a company is Jaguar Health?

Jaguar Health has a market capitalization of $27.52 million and generates $5.78 million in revenue each year. The biotechnology company earns $-38,540,000.00 in net income (profit) each year or ($6.89) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.